news
CDK4/6 and PARP combo improves prostate cancer treatment
Researchers at VHIO have discovered a new way to overcome drug resistance in metastatic prostate cancer – by combining CDK4/6 inhibitors with follow-up therapies.
List view / Grid view
Precision Medicine
news
New AI model PROTsi identifies aggressive tumours using protein markers
Researchers in Brazil and Poland have developed an AI-powered tool that predicts cancer aggressiveness by analysing protein expression - offering new insights into tumour behaviour.
news
€15M-backed tech targets tumour complexity
Paris-based One Biosciences, a precision oncology biotech company, has raised €15 million in Series A financing to accelerate the development of its AI-powered single-cell tumour profiling platform.
news
New standards for brain organoids aim to boost drug discovery
A new international framework introduces rigorous validity standards for the use of brain organoids and iPSC-derived models in studying neuropsychiatric disorders. These guidelines aim to accelerate drug discovery and bring precision treatments closer to reality.
article
The future of CNS drug development: signs of real progress
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
news
Targeting MAPK and PI3K/mTOR pathways halts ovarian cancer growth
A new preclinical study has combined two experimental drugs that effectively block ovarian tumour growth – a strategy that could lead to new treatments against this genetically complex cancer.
article
NGS is evolving: collaboration and tech lead the way
Next-generation sequencing (NGS) is advancing fast – and it’s not happening in isolation. Strategic partnerships and automation are streamlining workflows and reshaping what's possible in genomics research.
article
What single cells are revealing about brain disorders
Single-cell and spatial technologies are giving researchers an unprecedented view of how brain diseases like Alzheimer’s really work. The result? Faster discovery, clearer targets and a new path towards more effective treatments.
article
Smart automation for every lab, not just big pharma
Drug Target Review spoke with Giancarlo Basile at SLAS Europe 2025 about MGI’s bold shift from sequencing specialist to automation partner – helping research companies of all sizes achieve accuracy, speed and reproducibility.
news
Leukaemia-on-a-chip mimics bone marrow for better CAR T testing
A new “leukaemia-on-a-chip” device replicates human bone marrow and immune interactions, enabling researchers to observe CAR T cell therapies in action - potentially allowing for more personalised treatment strategies for leukaemia patients.
article
How dual-targeting ADCs aim to tackle resistance
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.
news
How bowel cancer beats treatment – and how AI can stop it
Scientists have developed a new AI-guided tool that predicts how bowel cancer becomes resistant to treatment – which could lead to development of new personalised therapies.
article
The AI model that is changing clinical trial design
AI is changing how clinical trials are run - quietly but significantly. Find out how digital twins are helping sponsors reduce control arms and accelerate development without changing trial endpoints.
article
The biotech mapping thousands of hidden therapeutic clues
Think drug discovery is slow? This biotech is moving faster, smarter and deeper – by asking the question that no one else has.
news
Why PARP inhibitors fail: key role of the CST complex in BRCA1-deficient cancers
Researchers from UT Health San Antonio have identified the CST protein complex as a key driver of resistance to PARP inhibitors in BRCA1-deficient cancers – which could lead to more personalised treatments for breast, ovarian and prostate cancer patients.
